433 related articles for article (PubMed ID: 21875091)
1. Meta-omic characterization of the marine invertebrate microbial consortium that produces the chemotherapeutic natural product ET-743.
Rath CM; Janto B; Earl J; Ahmed A; Hu FZ; Hiller L; Dahlgren M; Kreft R; Yu F; Wolff JJ; Kweon HK; Christiansen MA; Håkansson K; Williams RM; Ehrlich GD; Sherman DH
ACS Chem Biol; 2011 Nov; 6(11):1244-56. PubMed ID: 21875091
[TBL] [Abstract][Full Text] [Related]
2. Identification and analysis of the bacterial endosymbiont specialized for production of the chemotherapeutic natural product ET-743.
Schofield MM; Jain S; Porat D; Dick GJ; Sherman DH
Environ Microbiol; 2015 Oct; 17(10):3964-75. PubMed ID: 26013440
[TBL] [Abstract][Full Text] [Related]
3. Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem.
Cuevas C; Francesch A
Nat Prod Rep; 2009 Mar; 26(3):322-37. PubMed ID: 19240944
[TBL] [Abstract][Full Text] [Related]
4. Biosynthesis of Tetrahydroisoquinoline Antibiotics.
Tang GL; Tang MC; Song LQ; Zhang Y
Curr Top Med Chem; 2016; 16(15):1717-26. PubMed ID: 26456466
[TBL] [Abstract][Full Text] [Related]
5. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
6. A review of trabectedin (ET-743): a unique mechanism of action.
D'Incalci M; Galmarini CM
Mol Cancer Ther; 2010 Aug; 9(8):2157-63. PubMed ID: 20647340
[TBL] [Abstract][Full Text] [Related]
7. Ecteinascidins. A review of the chemistry, biology and clinical utility of potent tetrahydroisoquinoline antitumor antibiotics.
Le VH; Inai M; Williams RM; Kan T
Nat Prod Rep; 2015 Feb; 32(2):328-47. PubMed ID: 25273374
[TBL] [Abstract][Full Text] [Related]
8. Bacterial diversity associated with the Caribbean tunicate Ecteinascidia turbinata.
Pérez-Matos AE; Rosado W; Govind NS
Antonie Van Leeuwenhoek; 2007 Aug; 92(2):155-64. PubMed ID: 17265101
[TBL] [Abstract][Full Text] [Related]
9. Aquaculture of three phyla of marine invertebrates to yield bioactive metabolites: process developments and economics.
Mendola D
Biomol Eng; 2003 Jul; 20(4-6):441-58. PubMed ID: 12919831
[TBL] [Abstract][Full Text] [Related]
10. Discovery of an Antarctic Ascidian-Associated Uncultivated
Murray AE; Lo CC; Daligault HE; Avalon NE; Read RW; Davenport KW; Higham ML; Kunde Y; Dichosa AEK; Baker BJ; Chain PSG
mSphere; 2021 Dec; 6(6):e0075921. PubMed ID: 34851164
[TBL] [Abstract][Full Text] [Related]
11. Developing natural product drugs: Supply problems and how they have been overcome.
Newman DJ
Pharmacol Ther; 2016 Jun; 162():1-9. PubMed ID: 26706239
[TBL] [Abstract][Full Text] [Related]
12. Structure elucidation and 1H/13C NMR spectral assignments of four trabectedin related compounds.
Vermeulen W; Filliers W; García C; Manzanaro S; Montalvo D; Polanco C; Spillemaeckers F; Van Hoof B; Winderickx G; Somers I; Rodriguez-Campos I
Magn Reson Chem; 2008 Dec; 46(12):1198-202. PubMed ID: 18821578
[TBL] [Abstract][Full Text] [Related]
13. Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.
van Kesteren Ch; de Vooght MM; López-Lázaro L; Mathôt RA; Schellens JH; Jimeno JM; Beijnen JH
Anticancer Drugs; 2003 Aug; 14(7):487-502. PubMed ID: 12960733
[TBL] [Abstract][Full Text] [Related]
14. Preclinical and clinical results with the natural marine product ET-743.
D'Incalci M; Jimeno J
Expert Opin Investig Drugs; 2003 Nov; 12(11):1843-53. PubMed ID: 14585059
[TBL] [Abstract][Full Text] [Related]
15. Host control of symbiont natural product chemistry in cryptic populations of the tunicate Lissoclinum patella.
Kwan JC; Tianero MD; Donia MS; Wyche TP; Bugni TS; Schmidt EW
PLoS One; 2014; 9(5):e95850. PubMed ID: 24788869
[TBL] [Abstract][Full Text] [Related]
16. The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent.
Zewail-Foote M; Li VS; Kohn H; Bearss D; Guzman M; Hurley LH
Chem Biol; 2001 Nov; 8(11):1033-49. PubMed ID: 11731295
[TBL] [Abstract][Full Text] [Related]
17. DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin.
David-Cordonnier MH; Gajate C; Olmea O; Laine W; de la Iglesia-Vicente J; Perez C; Cuevas C; Otero G; Manzanares I; Bailly C; Mollinedo F
Chem Biol; 2005 Nov; 12(11):1201-10. PubMed ID: 16298299
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743).
Beumer JH; Lopez-Lazaro L; Schellens JH; Beijnen JH; van Tellingen O
Curr Clin Pharmacol; 2009 Jan; 4(1):38-42. PubMed ID: 19149499
[TBL] [Abstract][Full Text] [Related]
19. Marine natural products as anticancer drugs.
Simmons TL; Andrianasolo E; McPhail K; Flatt P; Gerwick WH
Mol Cancer Ther; 2005 Feb; 4(2):333-42. PubMed ID: 15713904
[TBL] [Abstract][Full Text] [Related]
20. In vitro studies on the metabolism of trabectedin (YONDELIS) in monkey and man, including human CYP reaction phenotyping.
Vermeir M; Hemeryck A; Cuyckens F; Francesch A; Bockx M; Van Houdt J; Steemans K; Mannens G; Avilés P; De Coster R
Biochem Pharmacol; 2009 May; 77(10):1642-54. PubMed ID: 19426702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
